Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 22, 2010

View Archived Issues

Apilimod mesilate has limited efficacy in phase II trial in rheumatoid arthritis

Dose increase authorized in Neovacs' ongoing IFN-alpha-kinoid phase I/II trial in SLE

BioSante Pharma sells Cold Genesys rights to its oncolytic virus technology

Nautilus and Tribute enter Canadian license agreement for Cambia to treat migraine

Lilly describes activity of LY-2606368, now in phase I testing

New HIF-1-alpha inhibitor P-2630 demonstrates oncolytic activity in vivo

Promising new antimalarial candidates investigated in preclinical testing

Spanish scientists present new inhibitors of PI3K/mTOR

Ampla Pharmaceuticals identifies novel cyclic amides

Theravance discloses novel inhibitors of 5HTT and NET

Cardero Therapeutics claims new inhibitors of mitochondrial permeability transition

St. Jude Medical acquires AGA Medical

FDA approves ready-to-use Nexterone premixed injection

Immunovaccine's phase I/II DPX-Survivac testing will target ovarian cancer

Fast Forward and Provid Pharma expand partnership to develop PV-267 in MS

Neuralstem submits IND to FDA for phase I trials of NSI-189 for depression

Halcygen Pharmaceuticals becomes Mayne Pharma Group

University of Michigan describes new 1,4-benzodiazepinone derivatives

Inspiration Biopharmaceuticals starts treatment in pivotal OBI-1 study

YM BioSciences expands phase I/II CYT-387 trial

BTG acquires Biocompatibles

Primary endpoint met in phase IIb Remimazolam trial in patients undergoing colonoscopy

Bayer and Regeneron report topline phase III data on VEGF Trap-Eye in wet AMD

Sylentis begins phase I/II SYL-040012 trial in patients with ocular hypertension

STATegics receives award from U.S. DoD to advance erythropoietin mimetics

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for December 24, 2024.
Enhanced Cognition: Lewy body dementia phase II pumps stock
BioWorld
Investors will get more details during the International Lewy Body Dementia Conference in Amsterdam late next month, but Wall Street is already buzzing about...
Experimental mRNA gene therapy suppresses preeclampsia in mice
BioWorld MedTech
A gene therapy based on an enhanced lipid nanoparticle (LNP) loaded with vascular endothelial growth factor (VEGF) mRNA could be developed for the treatment of...
Drug duo to Repare lack in gyno cancers? Phase I shows promise
BioWorld
Wall Street wasn’t jumping up and down about Repare Therapeutics Inc.’s early data in gynecological cancers, though the findings look positive and the company has...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.